Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Net Cash Flow came in at -$23.3 million in Q1 2026, up 90.35% YoY from -$12.3 million in Q1 2025, and down 141.97% on a QoQ basis from $55.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Net Cash Flow data on file, last reported at -$23.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 90.35% year-over-year to -$23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175.3 million (up 66.49% YoY) and the FY2025 annual result came in at -$393.6 million, down 2.61% from the prior year.
- Net Cash Flow eased to -$23.3 million in Q1 2026, from $55.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $55.6 million in Q4 2025 to a low of -$241.6 million in Q1 2025.
- A 5-year average of -$82.6 million and a median of -$94.5 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 557.67% — and 2025, when it soared 199.71%.
- Tracing DNA's Net Cash Flow over 5 years: stood at $23.0 million in 2022, then plunged by 557.67% to -$105.1 million in 2023, then soared by 47.0% to -$55.7 million in 2024, then soared by 199.71% to $55.6 million in 2025, then sank by 141.97% to -$23.3 million in 2026.
- The last three Net Cash Flow figures came in at -$23.3 million (Q1 2026), $55.6 million (Q4 2025), and -$94.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -16.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.70 Mn |
| Jun 30, 2026 | -16.70 Mn |
| Mar 31, 2026 | -23.32 Mn |
| Mar 31, 2026 | -23.32 Mn |
| Dec 31, 2025 | 55.56 Mn |
| Dec 31, 2025 | 55.56 Mn |
| Sep 30, 2025 | -94.48 Mn |
| Sep 30, 2025 | -94.48 Mn |
| Jun 30, 2025 | -113.01 Mn |
| Jun 30, 2025 | -113.01 Mn |
| Mar 31, 2025 | -241.64 Mn |
| Mar 31, 2025 | -241.64 Mn |
| Dec 31, 2024 | -55.72 Mn |
| Dec 31, 2024 | -55.72 Mn |
| Sep 30, 2024 | -114.17 Mn |
| Sep 30, 2024 | -114.17 Mn |
| Jun 30, 2024 | -111.46 Mn |
| Jun 30, 2024 | -111.46 Mn |
| Mar 31, 2024 | -102.21 Mn |
| Mar 31, 2024 | -102.21 Mn |